(R)-1,2-dioleoyl-3-trimethylammonium-propane–peptide complex (R-DOTAP–peptide complex) (R-DOTAP–peptide)

The (R)-1,2-dioleoyl-3-trimethylammonium-propane (R-DOTAP)–peptide complex is a nanoparticle-based immunotherapy platform designed to elicit a robust T-cell-mediated immune response. It consists of the R-enantiomer of the cationic lipid DOTAP complexed with specific peptide antigens, such as those derived from viral proteins or tumor-associated antigens (PDS Biotechnology, 2024). Unlike its racemic counterpart, R-DOTAP specifically activates the Type I interferon pathway, primarily through the induction of cytokines like CXCL10 and CCL2, which are critical for recruiting and activating dendritic cells (Schmaltz et al., 2014). Once internalized by dendritic cells, the complex facilitates the cross-presentation of the associated peptides on both MHC class I and class II molecules, leading to the generation of potent CD8+ killer T cells and CD4+ helper T cells (Wilk et al., 2020). This mechanism is leveraged in clinical-stage products like PDS1101 to treat HPV-related cancers by targeting the E6 and E7 oncoproteins (ClinicalTrials.gov, NCT04287374). The platform is characterized by its ability to promote a targeted immune response without the need for traditional external adjuvants, potentially reducing systemic toxicity while maintaining high efficacy (Bot et al., 2021).

Other names

VersamuneR-DOTAP nanoparticlesCationic lipid-peptide complexPDS1101 (when complexed with HPV peptides)R-DOTAP/Antigen complex

The complex activates the Type I interferon pathway (via MyD88/STING-independent or dependent mechanisms depending on context) and promotes the cross-presentation of peptides on MHC class I and II molecules in dendritic cells.